Grimes & Company’s Rocket Pharmaceuticals RCKT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$31.6K Hold
12,001
– – ﹤0.01% 461
2026
Q2
$41K Buy
12,001
+454
+4% +$1.51K ﹤0.01% 447
2026
Q1
$41.3K Sell
11,547
-1,098
-9% -$4.36K ﹤0.01% 432
2025
Q4
$44.4K Sell
12,645
-2,766
-18% -$9.47K ﹤0.01% 458
2025
Q3
$50.2K Buy
+15,411
New +$48.5K ﹤0.01% 449

Other funds holding RCKT

Grimes & Company's RCKT Position: Q3 2026 in Review

Grimes & Company held its Rocket Pharmaceuticals (RCKT) position steady in Q3 2026 at 12,001 shares worth $31.6K. The position accounts for ﹤0.01% of the portfolio, ranked #461.

Grimes & Company first reported a position in RCKT in Q3 2025 and has held it in 5 quarters since. The position peaked at $50.2K in Q3 2025. 174 funds tracked by Wall St. Rank hold RCKT as of Q3 2026.

  • Grimes & Company held 12,001 shares of Rocket Pharmaceuticals worth $31.6K as of Q3 2026.
  • Grimes & Company left its Rocket Pharmaceuticals share count unchanged in Q3 2026.
  • Rocket Pharmaceuticals made up ﹤0.01% of Grimes & Company's portfolio in Q3 2026, its #461 holding.
  • Grimes & Company first reported a position in Rocket Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
  • Grimes & Company's Rocket Pharmaceuticals position peaked at $50.2K in Q3 2025.
  • 174 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2026.

Based on Grimes & Company's 13F filing for Q3 2026, filed 29 Oct 2026.